28 Days vs 60 vs 90: The Evidence on Rehab Length

Ask the average person how long "rehab" lasts and they'll say 28 or 30 days. That's the default in film, TV, insurance forms, and public perception. It's also, per the actual outcome research, on the short end of what produces durable results — and it originated less as a clinical decision than as an insurance one.

This is the honest picture of what length-of-stay research shows, why longer generally wins, why 90 days is a specific inflection point, and how the cost math in Colombia changes what's financially possible for cash-pay patients. If you're deciding between programs, this is the framework the decision actually turns on.

Where the 28-day standard came from

The 28-day length isn't rooted in clinical trials. It emerged in the 1950s at the Hazelden Foundation in Minnesota, initially as a practical scheduling window rather than a clinically determined duration. It was then codified by mid-century commercial insurance policies, which adopted 28 days as a standard reimbursement period. By the 1980s the 28-day inpatient model was the American default.

Later research on outcomes didn't validate the 28-day cutoff — it just documented the pattern that already existed. The number persists because it's embedded in insurance benefit design, employer disability policies, and cultural expectation, not because outcome data pointed to it.

What the length-of-stay research actually shows

The National Institute on Drug Abuse's Principles of Drug Addiction Treatment summarizes decades of research with a specific recommendation: research indicates that most addicted individuals need at least three months in treatment to significantly reduce or stop their drug use, and the best outcomes occur with longer durations of treatment.

The evidence base for that summary includes:

• Retention as the mechanism. Multiple large studies of residential and long-term outpatient programs consistently find that time in treatment is one of the strongest predictors of post-treatment outcomes. Programs that retain patients longer produce better outcomes; patients who stay longer within programs do better than those who leave early.
• The 90-day inflection. Several outcome studies identify roughly 90 days as a point where the marginal benefit curve begins to flatten. Below 90 days, additional weeks produce large outcome gains. Above 90 days, additional weeks continue to help but with diminishing returns per week.
• Sub-30-day programs. Residential episodes of less than 30 days consistently show weaker outcomes than 30–90 day programs, and are often better characterized as extended detox or stabilization than as residential treatment proper.
• Behavioral and neurobiological rationale. Neurocognitive recovery from sustained heavy substance use — improvement in executive function, decision-making, emotion regulation — proceeds over months, not weeks. The clinical window during which residential treatment is intervening on impaired capacity extends well past 28 days for most patients.

Why longer generally wins

The clinical mechanisms explain the pattern:

• Neurocognitive recovery takes months. Executive function, working memory, and impulse control impairments related to heavy substance use recover partially in the first few weeks and continue to improve over months. Treatment work that requires those capacities (relapse prevention planning, insight-oriented therapy, complex skills training) is much more effective as those capacities return.
• Behavioral entrenchment takes time to modify. Substance-use behaviors are highly reinforced, environment-linked, and automatic. Building new behavioral patterns that can persist under stress requires sustained practice in a controlled environment.
• Comorbid conditions need time. Depression, anxiety, PTSD, and personality disorders that co-occur with substance use disorders don't stabilize on a 28-day timeline. Effective co-occurring treatment usually requires the longer window.
• Family and social system reconstruction. Repairing relationships, integrating family members into treatment, and building post-discharge support networks are relationship-heavy work that unfolds over months.
• Aftercare planning becomes real. A 28-day patient discharges with a plan on paper. A 90-day patient discharges with continuing-care relationships already established and infrastructure already in motion.

The 90-day inflection specifically

Several features cluster around the 90-day mark that make it a defensible clinical target:

• Post-acute withdrawal symptoms typically resolve or significantly reduce
• Sleep architecture normalizes for most patients
• Medication stabilization for co-occurring psychiatric conditions completes
• Peer relationships within the treatment cohort mature into durable support
• Family therapy work reaches meaningful depth
• Post-discharge continuing care infrastructure can be built with realistic timelines
• Employment and legal issues can be addressed with clinical support rather than deferred

None of these are hard cutoffs — they're statistical central tendencies. Some patients complete this work faster; some need longer. But 90 days as a clinical planning target has a stronger evidence base than 28.

Why 90-day programs are rare in the US

The cost math. A US premium residential program at $30,000–$50,000 per month makes a 90-day episode a six-figure decision, and most private insurance plans authorize progressively shorter residential stays with tighter medical necessity criteria as episodes lengthen. Cash-pay patients with a fixed treatment budget often make the tradeoff by opting for 30 days at a premium facility rather than 90 at a lower tier.

The choice architecture, in other words, is US-cost-driven, not clinically driven.

How the Colombia math changes the equation

Comparable-tier residential treatment in Colombia — English-language, physician-staffed, master's-level clinicians, medical detox capability, structured programming — typically runs in the following ranges in 2026:

The direct implication: for the cost of a 30-day US premium episode, a patient can typically fund a 60–90 day Colombia residential program at comparable clinical tier, and the length-of-stay research suggests the longer episode is likely to produce better outcomes.

This is the actual argument for treatment abroad in this vertical — not that Colombia is cheaper, but that the cost gap makes the clinically indicated length of stay financially feasible where it usually isn't domestically.

When shorter is right

Not every patient needs 90 days. Situations where a shorter residential episode is clinically appropriate:

• Motivated first-time treatment with mild-to-moderate SUD, strong pre-existing recovery scaffolding, and a low-risk post-discharge environment
• Step-up from IOP to short residential for stabilization, then step-down back to IOP
• Detox-and-brief-stabilization when the primary follow-through will be intensive outpatient or PHP
• Situational treatment (e.g., a specific stressor precipitated relapse, patient already has strong recovery infrastructure that requires re-establishment rather than construction)

For repeat episodes, moderate-to-severe SUD, co-occurring psychiatric conditions, environmental risk factors, or patients without strong pre-existing recovery infrastructure, the longer window is more defensible.

Beyond 90: does more help?

The research on residential stays over 90 days is thinner and less clean, but the pattern is generally: additional time continues to help but with diminishing returns per week, and continuing care outside the residential environment often produces similar outcomes at that point with lower cost and better real-world integration. For patients with severe SUD, dual diagnosis with severe psychiatric comorbidity, or high environmental risk, 6-month therapeutic community-style programs continue to have a role. For most patients, transitioning from 90-day residential to structured continuing care (IOP, sober living, monitored outpatient) at 90 days is a reasonable clinical inflection.

What to ask a program

1. What's your typical length of stay? What's your range?
2. How is length of stay determined for an individual patient?
3. What clinical criteria trigger extension recommendations?
4. How do you handle patients whose insurance authorizes less than you clinically recommend?
5. How is the transition from residential to continuing care structured?
6. What continuing care do you provide directly, and what do you coordinate elsewhere?

Bottom line

The 28-day standard is a historical and financial artifact, not a clinical one. Outcome research consistently supports 90 days as a defensible planning target for residential treatment of moderate-to-severe substance use disorders, especially for patients with co-occurring conditions or environmental risk factors. The financial barrier in the US makes 90-day programs uncommon domestically; the cost math in Colombia makes them feasible for cash-pay patients. This is not a marginal detail — it's the structural argument for medical tourism in this specific vertical.